BriaCell Therapeutics Corp.
BCTX · NASDAQ
7/31/2025 | 7/31/2024 | 7/31/2023 | 7/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $148 | $115 | $21 | $19 |
| Gross Profit | -$148 | -$115 | -$21 | -$19 |
| % Margin | – | – | – | – |
| R&D Expenses | $29,503 | $37,138 | $20,598 | $10,200 |
| G&A Expenses | $5,934 | $0 | $0 | $0 |
| SG&A Expenses | $5,934 | $8,292 | $10,638 | $9,221 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $2,149 | $0 | $0 | $0 |
| Operating Expenses | $37,586 | $45,430 | $31,236 | $19,421 |
| Operating Income | -$37,734 | -$45,545 | -$31,256 | -$19,440 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $900 | $38,806 | $3,989 | -$14,686 |
| Pre-Tax Income | -$36,834 | -$6,739 | -$27,268 | -$34,127 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$36,495 | -$6,547 | -$27,268 | -$34,127 |
| % Margin | – | – | – | – |
| EPS | -86.25 | -59.69 | -261.86 | -330.38 |
| % Growth | -44.5% | 77.2% | 20.7% | – |
| EPS Diluted | -86.25 | -59.69 | -261.86 | -330.38 |
| Weighted Avg Shares Out | 423 | 1,097 | 1,041 | 1,033 |
| Weighted Avg Shares Out Dil | 423 | 1,097 | 1,041 | 1,033 |
| Supplemental Information | – | – | – | – |
| Interest Income | $166 | $394 | $1,197 | $174 |
| Interest Expense | $51 | $0 | $0 | $1 |
| Depreciation & Amortization | $148 | $115 | $21 | $19 |
| EBITDA | -$36,635 | -$6,624 | -$27,247 | -$34,106 |
| % Margin | – | – | – | – |